Ali Behbahani

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Spyglass Ophthalmics, Inc. develops products for vision and eye care. The company was founded by Malik Y. Kahook and Glenn Sussman and is headquartered in Mission Viejo, CA.

ClarVista Medical, Inc. operates as a medical device company which focuses on the novel solutions in ophthalmology. It develops the harmoni modular intra-ocular lens systems to optimize vision in the setting of cataract surgery. The company was founded by Paul McLean and Robert E. Atkinson in 2012 and is headquartered in Aliso Viejo, CA.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

Ocutherix, Inc. operates as a medical device incubator which focuses on novel medical technologies. The firm serves the ophthalmology, cardiology, mobile health, orthopedics, neurology, pulmonology and metabolic clinical solutions. The company was founded by Robert E. Atkinson in 2005 and is headquartered in Stillwater, MN.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Cardionomic, Inc. engages in the development of medical devices. The company was founded in 2011 and is headquartered in New Brighton, MN.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Ivantis, Inc. develops technology to treat ophthalmic diseases. The firm develops solutions for glaucoma and offers an intracanalicular scaffold or implantable device that relieves high intraocular pressures in patients. It provides its solutions for use in clinical trials to ophthalmology specialists. Ivantis was founded in 2007 and is headquartered in Irvine, CA.

Rotation Medical, Inc. develops treatment of rotator cuff disease. It includes a bioinductive implant and a set of disposable arthroscopic instruments that has been shown to heal tendons by inducing the growth of new tendon-like tissue. The company was founded by Thomas R. Hektner in 2009 and is headquartered in Plymouth, MN.

Rotation Medical, Inc. develops treatment of rotator cuff disease. It includes a bioinductive implant and a set of disposable arthroscopic instruments that has been shown to heal tendons by inducing the growth of new tendon-like tissue. The company was founded by Thomas R. Hektner in 2009 and is headquartered in Plymouth, MN.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.

Spyglass Ophthalmics, Inc. develops products for vision and eye care. The company was founded by Malik Y. Kahook and Glenn Sussman and is headquartered in Mission Viejo, CA.

ClarVista Medical, Inc. operates as a medical device company which focuses on the novel solutions in ophthalmology. It develops the harmoni modular intra-ocular lens systems to optimize vision in the setting of cataract surgery. The company was founded by Paul McLean and Robert E. Atkinson in 2012 and is headquartered in Aliso Viejo, CA.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Rotation Medical, Inc. develops treatment of rotator cuff disease. It includes a bioinductive implant and a set of disposable arthroscopic instruments that has been shown to heal tendons by inducing the growth of new tendon-like tissue. The company was founded by Thomas R. Hektner in 2009 and is headquartered in Plymouth, MN.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Ivantis, Inc. develops technology to treat ophthalmic diseases. The firm develops solutions for glaucoma and offers an intracanalicular scaffold or implantable device that relieves high intraocular pressures in patients. It provides its solutions for use in clinical trials to ophthalmology specialists. Ivantis was founded in 2007 and is headquartered in Irvine, CA.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022.